[EN] SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS [FR] LIGANDS SÉLECTIFS DE LA FKBP51 DESTINÉS AU TRAITEMENT DE TROUBLES PSYCHIATRIQUES
Carbamates and ureas as modifiers of multi-drug resistance
申请人:Vertex Pharmaceuticals Incorporated
公开号:US05744485A1
公开(公告)日:1998-04-28
The present invention relates to compounds that can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, and for use in multi-drug resistant cancer therapy.
Novel carbamates and ureas as modifiers of multi-drug resistance
申请人:VERTEX PHARMACEUTICALS INCORPORATED
公开号:EP1138673A2
公开(公告)日:2001-10-04
The present invention relates to compounds as represented by formula (I) that can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. This invention also comprises pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of multi-drug resistance and for use in multi-drug resistant cancer therapy.
Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors
申请人:Vertex Pharmceuticals Incorporated
公开号:EP1666053A1
公开(公告)日:2006-06-07
The present invention relates to methods and pharmaceutical compositions for stimulating the growth of neurites in nerve cells. The compositions comprise a neurotrophic amount of a compound and a neurotrophic factor, such as nerve growth factor (NGF). The methods comprise treating nerve cells with the above compositions or compositions comprising the compound without a neurotrophic factor. The methods of this invention can be used to promote repair of neuronal damage caused by disease or physical trauma.
Selective FKBP51 ligands for treatment of psychiatric disorders
申请人:Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
公开号:US10246413B2
公开(公告)日:2019-04-02
The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.